CLIPSing Melanotan-II Reveals New Selective Melanocortin Receptor Agonists

The melanocortin system plays a crucial role in diverse physiological processes, including pigmentation, energy homeostasis, and sexual function, through its G protein-coupled receptors (GPCRs), the melanocortin receptors (MCRs). While non-selective agonists like Melanotan-II (MT-II) exist, their broad activity across multiple MCR subtypes (MC1R, MC3R, MC4R, MC5R) often leads to undesirable side effects. Developing compounds that selectively activate specific MCR subtypes or specific signaling pathways (functional selectivity) is critical to unlock their therapeutic potential with improved safety profiles.

This study successfully identified multiple novel Melanotan-II analogs exhibiting functional selectivity at human melanocortin receptors. While specific quantitative data (e.g., EC50 values, fold-changes in signaling) are not provided in the available information, the research demonstrated that these CLIPSed peptides could differentially activate cAMP signaling and β-arrestin recruitment pathways across various hMCR subtypes. This functional selectivity suggests a potential for improved therapeutic windows compared to non-selective parent compounds, offering a significant advantage in drug design. The findings indicate a successful strategy for overcoming the limitations of broad-spectrum melanocortin agonists. The key finding is the successful discovery of novel Melanotan-II derivatives that act as functionally selective agonists for human melanocortin receptors, paving the way for more targeted therapeutic interventions.